(Q38455547)

3 September 2017

title

HER-2/neu is overexpressed infrequently in patients with prostate carcinoma. Results from the California Cancer Consortium Screening Trial (English)

1 reference

3 September 2017

0 references

1 reference

10

David R Gandara

1 reference

3 September 2017

Primo N Lara

1

1 reference

3 September 2017

Frederick J Meyers

2

1 reference

3 September 2017

Carl R Gray

3

1 reference

3 September 2017

Regina Gandour Edwards

4

1 reference

3 September 2017

Paul H Gumerlock

5

1 reference

3 September 2017

Caren Kauderer

6

1 reference

3 September 2017

Garrett Tichauer

7

1 reference

3 September 2017

Przemyslaw Twardowski

8

1 reference

3 September 2017

James H Doroshow

9

1 reference

3 September 2017

language of work or name

English

0 references

publication date

1 May 2002

1 reference

3 September 2017

1 reference

3 September 2017

volume

94

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

2584-2589

1 reference

3 September 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Treatment options in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Transfected neu oncogene induces human prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Circulating tumor markers in breast cancer: accepted utilities and novel prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Overexpression of HER2/neu in solid tumours: an immunohistochemical survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Prognostic value of immunohistochemical expression of the c-erbB-2 oncoprotein in metastasic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10526

21 January 2018

Identifiers

DOI

10.1002/CNCR.10526

1 reference

3 September 2017

1 reference